6850.TWO BiOptic Inc.
- Market cap
- TWD 936M
- P/E
- 104.8x
- P/B
- 2.19x
- ROE
- 4.8%
- Dividend yield
- 0.57%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2025.
Is 6850.TWO undervalued?
Graham numberThe Graham number of BiOptic Inc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BiOptic Inc. fundamental analysis
No fundamental analysis for BiOptic Inc. yet.
BiOptic Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BiOptic Inc.
BiOptic Inc., a biotechnology instrumentation company, develops scientific products for research and clinical applications. It offers instruments, such as bio-fragment analyzers and PCR thermocyclers; consumables, including DNA, RNA, and protein cartridges, as well as quantification kits; premix and polymerase PCR reagents; and veterinary, human, and food related testing kits. BiOptic Inc.was founded in 1993 and is headquartered in New Taipei City, Taiwan.
Full company profileBiOptic Inc. financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
BiOptic Inc. annual financial statements
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 62.1M | 92.0M | 124M | 179M | 231M | 228M | 203M | 429M |
| Gross Profit | 26.7M | 50.6M | 79.2M | 110M | 153M | 153M | 125M | 272M |
| Operating Income | -15.9M | 3.46M | 27.0M | 44.2M | 65.0M | 44.1M | 19.2M | 73.2M |
| EBITDA | -11.1M | 7.13M | 32.1M | 57.4M | 88.9M | 65.0M | 46.6M | 57.8M |
| Net Income | -14.7M | 2.19M | 25.9M | 46.3M | 61.3M | 37.7M | 22.7M | 21.0M |
| EPS | -0.83 | 0.12 | 1.30 | 1.84 | 2.02 | 1.25 | 0.75 | 0.64 |
| Balance Sheet | ||||||||
| Total Assets | - | - | 291M | 419M | 521M | 614M | 596M | 593M |
| Total Liabilities | - | - | 110M | 44.7M | 94.1M | 171M | 135M | 143M |
| Shareholders' Equity | - | - | 180M | 368M | 419M | 432M | 450M | 438M |
| Cash & Short-term Investments | - | 49.0M | 76.0M | 164M | 207M | 80.6M | 98.1M | 188M |
| Total Debt | - | - | 86.1M | 5.86M | 14.3M | 93.2M | 86.2M | - |
| Cash Flow | ||||||||
| Operating Cash Flow | - | - | 14.6M | 32.4M | 69.5M | -12.7M | 31.1M | 133M |
| Capital Expenditure | - | - | 1.03M | 7.68M | 6.88M | 114M | 6.79M | 2.22M |
| Free Cash Flow | - | - | 11.9M | 24.7M | 62.6M | -127M | 24.3M | 131M |
| Ratios | ||||||||
| ROE | - | - | 14.4% | 12.6% | 14.6% | 8.7% | 5.1% | 4.8% |
| ROA | - | - | 8.9% | 11.0% | 11.8% | 6.1% | 3.8% | 3.5% |
| Net Profit Margin | -23.7% | 2.4% | 21.0% | 25.8% | 26.5% | 16.5% | 11.2% | 4.9% |
| Debt to Equity | - | - | 0.48x | 0.02x | 0.03x | 0.22x | 0.19x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BiOptic Inc. dividends
- Dividend yield
- 0.57%
- Forward dividend
- 0.50 TWD
- Payout ratio
- 23.4%
- Ex-dividend date
- Aug 25, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2024 | TWD 5.32M | 0.18 | 23.4% |
| 2023 | TWD 24.2M | 0.80 | 64.1% |
| 2022 | TWD 11.0M | 0.36 | 18.0% |
| 2021 | - | - | - |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1100:1000 on Aug 20, 2025.
Who owns BiOptic Inc.
Ownership data of BiOptic Inc. is not available yet.
BiOptic Inc. company profile
- Company name
- BiOptic Inc.
- Ticker
- 6850.TWO
- ISIN
- TW0006850001
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 108-3, Minquan Road, New Taipei City, Taiwan
- Phone
- 886 2 2218 8726
- Website
- bioptic.com.tw
About BiOptic Inc.
BiOptic Inc., a biotechnology instrumentation company, develops scientific products for research and clinical applications. It offers instruments, such as bio-fragment analyzers and PCR thermocyclers; consumables, including DNA, RNA, and protein cartridges, as well as quantification kits; premix and polymerase PCR reagents; and veterinary, human, and food related testing kits. BiOptic Inc.was founded in 1993 and is headquartered in New Taipei City, Taiwan.